Protective Efficacy of Multiple Epitope-Based Vaccine against IHyalomma anatolicum/I, Vector of ITheileria annulata/I and Crimean–Congo Hemorrhagic Fever Virus

Hyalomma anatolicum is the principal vector for Theileria annulata, T. equi, and T. Lestoquardi in animals and the Crimean–Congo hemorrhagic fever virus in humans. Due to the gradual loss of efficacy of the available acaricides against field tick populations, the development of phytoacaricides and v...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccines (Basel) 2023-04, Vol.11 (4)
Hauptverfasser: Nandi, Abhijit, Manisha, Solanki, Vandana, Tiwari, Vishvanath, Sajjanar, Basavaraj, Sankar, Muthu, Saini, Mohini, Shrivastava, Sameer, Bhure, S. K, Ghosh, Srikant
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 4
container_start_page
container_title Vaccines (Basel)
container_volume 11
creator Nandi, Abhijit
Manisha
Solanki, Vandana
Tiwari, Vishvanath
Sajjanar, Basavaraj
Sankar, Muthu
Saini, Mohini
Shrivastava, Sameer
Bhure, S. K
Ghosh, Srikant
description Hyalomma anatolicum is the principal vector for Theileria annulata, T. equi, and T. Lestoquardi in animals and the Crimean–Congo hemorrhagic fever virus in humans. Due to the gradual loss of efficacy of the available acaricides against field tick populations, the development of phytoacaricides and vaccines has been considered the two most critical components of the integrated tick management strategies. In the present study, in order to induce both cellular and humoral immune responses in the host against H. anatolicum, two multi-epitopic peptides (MEPs), i.e., VT1 and VT2, were designed. The immune-stimulating potential of the constructs was determined by in silicoinvestigation on allergenicity (non-allergen, antigenic (0.46 and 1.0046)), physicochemical properties (instability index 27.18 and 35.46), as well as the interaction of constructs with TLRs by docking and molecular dynamics analysis. The immunization efficacy of the MEPs mixed with 8% Montanide[sup.TM] gel 01 PR against H. anatolicum larvae was determined as 93.3% and 96.9% in VT1- and VT2-immunized rabbits, respectively. Against adults, the efficacy was 89.9% and 86.4% in VT1- and VT2-immunized rabbits, respectively. A significant (p < 0.001) reduction in the anti-inflammatory cytokine (IL-4) and significantly higher IgG response was observed in a VT1-immunized group of rabbits as compared with the response observed in the control group. However, in the case of the VT2-immunized rabbits, an elevated anti-VT2 IgG and pro-inflammatory cytokine (IL-2) (>30 fold) along with a decreased level of anti-inflammatory cytokine IL-4 (0.75 times) was noted. The efficacy of MEP and its potential immune stimulatory responses indicate that it might be useful for tick management.
doi_str_mv 10.3390/vaccines11040881
format Article
fullrecord <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracmisc_A747541177</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A747541177</galeid><sourcerecordid>A747541177</sourcerecordid><originalsourceid>FETCH-LOGICAL-g677-2fdb7450f3f85331e343e45170ed72e85cb9a396fe94d2af05a6686c3536b5c83</originalsourceid><addsrcrecordid>eNptj8FKw0AQhhdRsNTePS54Ne1uNskmxxpaG6jooRRvZbqZTVeSbNkkhd58B5_AV_NJTKmHHpw5zM_wz_czhNxzNhYiYZMDKGVqbDhnAYtjfkUGPpORJxLxfn2hb8moaT5YXwkXcSQH5PvN2RZVaw5IZ1obBepIraYvXdmafdkv96a1e_SeoMGcrs9BFAowddPSbHGE0lYVUKihtaVRXTXJHum6R1p3AmWrHZoSnTlZ6q6EFiZZL3OaOlMh1D-fX6mtC0sXWFnndlAYRed4QEfXxnXNHbnRUDY4-ptDsprPVunCW74-Z-l06RWRlJ6v860MQqaFjkMhOIpAYBByyTCXPsah2iYgkkhjEuQ-aBZCFMWREqGItqGKxZA8nLEFlLgxtbatA1WZRm2mMpBhwLmUvWv8j6vvHCujbI26__Xy4Bc5FoBx</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Protective Efficacy of Multiple Epitope-Based Vaccine against IHyalomma anatolicum/I, Vector of ITheileria annulata/I and Crimean–Congo Hemorrhagic Fever Virus</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Nandi, Abhijit ; Manisha ; Solanki, Vandana ; Tiwari, Vishvanath ; Sajjanar, Basavaraj ; Sankar, Muthu ; Saini, Mohini ; Shrivastava, Sameer ; Bhure, S. K ; Ghosh, Srikant</creator><creatorcontrib>Nandi, Abhijit ; Manisha ; Solanki, Vandana ; Tiwari, Vishvanath ; Sajjanar, Basavaraj ; Sankar, Muthu ; Saini, Mohini ; Shrivastava, Sameer ; Bhure, S. K ; Ghosh, Srikant</creatorcontrib><description>Hyalomma anatolicum is the principal vector for Theileria annulata, T. equi, and T. Lestoquardi in animals and the Crimean–Congo hemorrhagic fever virus in humans. Due to the gradual loss of efficacy of the available acaricides against field tick populations, the development of phytoacaricides and vaccines has been considered the two most critical components of the integrated tick management strategies. In the present study, in order to induce both cellular and humoral immune responses in the host against H. anatolicum, two multi-epitopic peptides (MEPs), i.e., VT1 and VT2, were designed. The immune-stimulating potential of the constructs was determined by in silicoinvestigation on allergenicity (non-allergen, antigenic (0.46 and 1.0046)), physicochemical properties (instability index 27.18 and 35.46), as well as the interaction of constructs with TLRs by docking and molecular dynamics analysis. The immunization efficacy of the MEPs mixed with 8% Montanide[sup.TM] gel 01 PR against H. anatolicum larvae was determined as 93.3% and 96.9% in VT1- and VT2-immunized rabbits, respectively. Against adults, the efficacy was 89.9% and 86.4% in VT1- and VT2-immunized rabbits, respectively. A significant (p &lt; 0.001) reduction in the anti-inflammatory cytokine (IL-4) and significantly higher IgG response was observed in a VT1-immunized group of rabbits as compared with the response observed in the control group. However, in the case of the VT2-immunized rabbits, an elevated anti-VT2 IgG and pro-inflammatory cytokine (IL-2) (&gt;30 fold) along with a decreased level of anti-inflammatory cytokine IL-4 (0.75 times) was noted. The efficacy of MEP and its potential immune stimulatory responses indicate that it might be useful for tick management.</description><identifier>ISSN: 2076-393X</identifier><identifier>EISSN: 2076-393X</identifier><identifier>DOI: 10.3390/vaccines11040881</identifier><language>eng</language><publisher>MDPI AG</publisher><subject>Crimean hemorrhagic fever ; Distribution ; Dosage and administration ; Drug therapy ; Parasite vaccines ; Prevention ; Testing</subject><ispartof>Vaccines (Basel), 2023-04, Vol.11 (4)</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids></links><search><creatorcontrib>Nandi, Abhijit</creatorcontrib><creatorcontrib>Manisha</creatorcontrib><creatorcontrib>Solanki, Vandana</creatorcontrib><creatorcontrib>Tiwari, Vishvanath</creatorcontrib><creatorcontrib>Sajjanar, Basavaraj</creatorcontrib><creatorcontrib>Sankar, Muthu</creatorcontrib><creatorcontrib>Saini, Mohini</creatorcontrib><creatorcontrib>Shrivastava, Sameer</creatorcontrib><creatorcontrib>Bhure, S. K</creatorcontrib><creatorcontrib>Ghosh, Srikant</creatorcontrib><title>Protective Efficacy of Multiple Epitope-Based Vaccine against IHyalomma anatolicum/I, Vector of ITheileria annulata/I and Crimean–Congo Hemorrhagic Fever Virus</title><title>Vaccines (Basel)</title><description>Hyalomma anatolicum is the principal vector for Theileria annulata, T. equi, and T. Lestoquardi in animals and the Crimean–Congo hemorrhagic fever virus in humans. Due to the gradual loss of efficacy of the available acaricides against field tick populations, the development of phytoacaricides and vaccines has been considered the two most critical components of the integrated tick management strategies. In the present study, in order to induce both cellular and humoral immune responses in the host against H. anatolicum, two multi-epitopic peptides (MEPs), i.e., VT1 and VT2, were designed. The immune-stimulating potential of the constructs was determined by in silicoinvestigation on allergenicity (non-allergen, antigenic (0.46 and 1.0046)), physicochemical properties (instability index 27.18 and 35.46), as well as the interaction of constructs with TLRs by docking and molecular dynamics analysis. The immunization efficacy of the MEPs mixed with 8% Montanide[sup.TM] gel 01 PR against H. anatolicum larvae was determined as 93.3% and 96.9% in VT1- and VT2-immunized rabbits, respectively. Against adults, the efficacy was 89.9% and 86.4% in VT1- and VT2-immunized rabbits, respectively. A significant (p &lt; 0.001) reduction in the anti-inflammatory cytokine (IL-4) and significantly higher IgG response was observed in a VT1-immunized group of rabbits as compared with the response observed in the control group. However, in the case of the VT2-immunized rabbits, an elevated anti-VT2 IgG and pro-inflammatory cytokine (IL-2) (&gt;30 fold) along with a decreased level of anti-inflammatory cytokine IL-4 (0.75 times) was noted. The efficacy of MEP and its potential immune stimulatory responses indicate that it might be useful for tick management.</description><subject>Crimean hemorrhagic fever</subject><subject>Distribution</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Parasite vaccines</subject><subject>Prevention</subject><subject>Testing</subject><issn>2076-393X</issn><issn>2076-393X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNptj8FKw0AQhhdRsNTePS54Ne1uNskmxxpaG6jooRRvZbqZTVeSbNkkhd58B5_AV_NJTKmHHpw5zM_wz_czhNxzNhYiYZMDKGVqbDhnAYtjfkUGPpORJxLxfn2hb8moaT5YXwkXcSQH5PvN2RZVaw5IZ1obBepIraYvXdmafdkv96a1e_SeoMGcrs9BFAowddPSbHGE0lYVUKihtaVRXTXJHum6R1p3AmWrHZoSnTlZ6q6EFiZZL3OaOlMh1D-fX6mtC0sXWFnndlAYRed4QEfXxnXNHbnRUDY4-ptDsprPVunCW74-Z-l06RWRlJ6v860MQqaFjkMhOIpAYBByyTCXPsah2iYgkkhjEuQ-aBZCFMWREqGItqGKxZA8nLEFlLgxtbatA1WZRm2mMpBhwLmUvWv8j6vvHCujbI26__Xy4Bc5FoBx</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>Nandi, Abhijit</creator><creator>Manisha</creator><creator>Solanki, Vandana</creator><creator>Tiwari, Vishvanath</creator><creator>Sajjanar, Basavaraj</creator><creator>Sankar, Muthu</creator><creator>Saini, Mohini</creator><creator>Shrivastava, Sameer</creator><creator>Bhure, S. K</creator><creator>Ghosh, Srikant</creator><general>MDPI AG</general><scope/></search><sort><creationdate>20230401</creationdate><title>Protective Efficacy of Multiple Epitope-Based Vaccine against IHyalomma anatolicum/I, Vector of ITheileria annulata/I and Crimean–Congo Hemorrhagic Fever Virus</title><author>Nandi, Abhijit ; Manisha ; Solanki, Vandana ; Tiwari, Vishvanath ; Sajjanar, Basavaraj ; Sankar, Muthu ; Saini, Mohini ; Shrivastava, Sameer ; Bhure, S. K ; Ghosh, Srikant</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g677-2fdb7450f3f85331e343e45170ed72e85cb9a396fe94d2af05a6686c3536b5c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Crimean hemorrhagic fever</topic><topic>Distribution</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Parasite vaccines</topic><topic>Prevention</topic><topic>Testing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nandi, Abhijit</creatorcontrib><creatorcontrib>Manisha</creatorcontrib><creatorcontrib>Solanki, Vandana</creatorcontrib><creatorcontrib>Tiwari, Vishvanath</creatorcontrib><creatorcontrib>Sajjanar, Basavaraj</creatorcontrib><creatorcontrib>Sankar, Muthu</creatorcontrib><creatorcontrib>Saini, Mohini</creatorcontrib><creatorcontrib>Shrivastava, Sameer</creatorcontrib><creatorcontrib>Bhure, S. K</creatorcontrib><creatorcontrib>Ghosh, Srikant</creatorcontrib><jtitle>Vaccines (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nandi, Abhijit</au><au>Manisha</au><au>Solanki, Vandana</au><au>Tiwari, Vishvanath</au><au>Sajjanar, Basavaraj</au><au>Sankar, Muthu</au><au>Saini, Mohini</au><au>Shrivastava, Sameer</au><au>Bhure, S. K</au><au>Ghosh, Srikant</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Protective Efficacy of Multiple Epitope-Based Vaccine against IHyalomma anatolicum/I, Vector of ITheileria annulata/I and Crimean–Congo Hemorrhagic Fever Virus</atitle><jtitle>Vaccines (Basel)</jtitle><date>2023-04-01</date><risdate>2023</risdate><volume>11</volume><issue>4</issue><issn>2076-393X</issn><eissn>2076-393X</eissn><abstract>Hyalomma anatolicum is the principal vector for Theileria annulata, T. equi, and T. Lestoquardi in animals and the Crimean–Congo hemorrhagic fever virus in humans. Due to the gradual loss of efficacy of the available acaricides against field tick populations, the development of phytoacaricides and vaccines has been considered the two most critical components of the integrated tick management strategies. In the present study, in order to induce both cellular and humoral immune responses in the host against H. anatolicum, two multi-epitopic peptides (MEPs), i.e., VT1 and VT2, were designed. The immune-stimulating potential of the constructs was determined by in silicoinvestigation on allergenicity (non-allergen, antigenic (0.46 and 1.0046)), physicochemical properties (instability index 27.18 and 35.46), as well as the interaction of constructs with TLRs by docking and molecular dynamics analysis. The immunization efficacy of the MEPs mixed with 8% Montanide[sup.TM] gel 01 PR against H. anatolicum larvae was determined as 93.3% and 96.9% in VT1- and VT2-immunized rabbits, respectively. Against adults, the efficacy was 89.9% and 86.4% in VT1- and VT2-immunized rabbits, respectively. A significant (p &lt; 0.001) reduction in the anti-inflammatory cytokine (IL-4) and significantly higher IgG response was observed in a VT1-immunized group of rabbits as compared with the response observed in the control group. However, in the case of the VT2-immunized rabbits, an elevated anti-VT2 IgG and pro-inflammatory cytokine (IL-2) (&gt;30 fold) along with a decreased level of anti-inflammatory cytokine IL-4 (0.75 times) was noted. The efficacy of MEP and its potential immune stimulatory responses indicate that it might be useful for tick management.</abstract><pub>MDPI AG</pub><doi>10.3390/vaccines11040881</doi></addata></record>
fulltext fulltext
identifier ISSN: 2076-393X
ispartof Vaccines (Basel), 2023-04, Vol.11 (4)
issn 2076-393X
2076-393X
language eng
recordid cdi_gale_infotracmisc_A747541177
source PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Crimean hemorrhagic fever
Distribution
Dosage and administration
Drug therapy
Parasite vaccines
Prevention
Testing
title Protective Efficacy of Multiple Epitope-Based Vaccine against IHyalomma anatolicum/I, Vector of ITheileria annulata/I and Crimean–Congo Hemorrhagic Fever Virus
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T16%3A48%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Protective%20Efficacy%20of%20Multiple%20Epitope-Based%20Vaccine%20against%20IHyalomma%20anatolicum/I,%20Vector%20of%20ITheileria%20annulata/I%20and%20Crimean%E2%80%93Congo%20Hemorrhagic%20Fever%20Virus&rft.jtitle=Vaccines%20(Basel)&rft.au=Nandi,%20Abhijit&rft.date=2023-04-01&rft.volume=11&rft.issue=4&rft.issn=2076-393X&rft.eissn=2076-393X&rft_id=info:doi/10.3390/vaccines11040881&rft_dat=%3Cgale%3EA747541177%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A747541177&rfr_iscdi=true